IRIS Accounts Production v24.1.9.2 13558857 Board of Directors 1.4.23 31.3.24 31.3.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh135588572023-03-31135588572024-03-31135588572023-04-012024-03-31135588572022-03-31135588572022-04-012023-03-31135588572023-03-3113558857ns15:EnglandWales2023-04-012024-03-3113558857ns14:PoundSterling2023-04-012024-03-3113558857ns10:Director12023-04-012024-03-3113558857ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3113558857ns10:SmallEntities2023-04-012024-03-3113558857ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3113558857ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3113558857ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3113558857ns10:FullAccounts2023-04-012024-03-3113558857ns10:Director32023-04-012024-03-3113558857ns10:Director52023-04-012024-03-3113558857ns10:Director62023-04-012024-03-3113558857ns10:RegisteredOffice2023-04-012024-03-3113558857ns5:CurrentFinancialInstruments2024-03-3113558857ns5:CurrentFinancialInstruments2023-03-3113558857ns5:Non-currentFinancialInstruments2024-03-3113558857ns5:Non-currentFinancialInstruments2023-03-3113558857ns5:ShareCapital2024-03-3113558857ns5:ShareCapital2023-03-3113558857ns5:SharePremium2024-03-3113558857ns5:SharePremium2023-03-3113558857ns5:CapitalRedemptionReserve2024-03-3113558857ns5:CapitalRedemptionReserve2023-03-3113558857ns5:RetainedEarningsAccumulatedLosses2024-03-3113558857ns5:RetainedEarningsAccumulatedLosses2023-03-3113558857ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3113558857ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-3113558857ns5:Non-currentFinancialInstruments2023-04-012024-03-31
REGISTERED NUMBER: 13558857 (England and Wales)










FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

FOR

ADENDRA THERAPEUTICS LIMITED

ADENDRA THERAPEUTICS LIMITED (REGISTERED NUMBER: 13558857)






CONTENTS OF THE FINANCIAL STATEMENTS
for the Year Ended 31 MARCH 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


ADENDRA THERAPEUTICS LIMITED

COMPANY INFORMATION
for the Year Ended 31 MARCH 2024







DIRECTORS: Dr R Mehta
Dr C Reis E Sousa
Ms D Hackett
Dr J Tobin





REGISTERED OFFICE: Five Ways
57-59 Hatfield Road
Potters Bar
Hertfordshire
EN6 1HS





REGISTERED NUMBER: 13558857 (England and Wales)





ACCOUNTANTS: SRG Newmans Limited
Five Ways
57-59 Hatfield Road
Potters Bar
Hertfordshire
EN6 1HS

ADENDRA THERAPEUTICS LIMITED (REGISTERED NUMBER: 13558857)

BALANCE SHEET
31 MARCH 2024

2024 2023
Notes £    £   
CURRENT ASSETS
Debtors 4 499,199 276,210
Cash at bank 778,119 428,888
1,277,318 705,098
CREDITORS
Amounts falling due within one year 5 289,340 83,203
NET CURRENT ASSETS 987,978 621,895
TOTAL ASSETS LESS CURRENT
LIABILITIES

987,978

621,895

CREDITORS
Amounts falling due after more than one
year (including convertible debt)

6

810,917

-
NET ASSETS 177,061 621,895

CAPITAL AND RESERVES
Called up share capital 28 44
Share premium 965 2,022,140
Capital redemption reserve 2,221,263 -
Retained earnings (2,045,195 ) (1,400,289 )
SHAREHOLDERS' FUNDS 177,061 621,895

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

ADENDRA THERAPEUTICS LIMITED (REGISTERED NUMBER: 13558857)

BALANCE SHEET - continued
31 MARCH 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 5 August 2024 and were signed on its behalf by:





Dr R Mehta - Director


ADENDRA THERAPEUTICS LIMITED (REGISTERED NUMBER: 13558857)

NOTES TO THE FINANCIAL STATEMENTS
for the Year Ended 31 MARCH 2024

1. STATUTORY INFORMATION

Adendra Therapeutics Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

ADENDRA THERAPEUTICS LIMITED (REGISTERED NUMBER: 13558857)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 31 MARCH 2024

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2023 - 1 ) .

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Other debtors 499,199 276,210

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 27,750 38,062
Amounts owed to group undertakings - 22,174
Taxation and social security 31,512 2,921
Other creditors 230,078 20,046
289,340 83,203

6. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN
ONE YEAR
2024 2023
£    £   
Other creditors 810,917 -

Included within long term liabilities are convertible loan notes, amounting to £810,030. There is interest of 6% on the loan notes and is due to expire on 20 September 2025.

7. ULTIMATE CONTROLLING PARTY

The ultimate controlling parties are; Dr C Reis e Sousa and Dr R Mehta, by virtue of their shareholding.